Eric Dube, Ph.D.
President and Chief Executive Officer
Dr. Dube is the president and chief executive officer of Retrophin and serves as a member of the company's board of directors. He is a results-driven leader who is committed to patients and integrating their perspective into all aspects of the company’s operations. At Retrophin, Dr. Dube oversees a global team of 225+ employees who are dedicated to identifying, developing and delivering life-changing therapies to people living with rare disease, as well as the advancement of the company’s promising pipeline featuring an innovative product candidate with first-in-class potential. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions. He leads with a commitment to patients, integrating their perspective into all aspects of the company's operations.
Prior to joining Retrophin, Dr. Dube was president and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy and investment decisions for the company's North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain and alliance management. During Dr. Dube's tenure at GSK, he also led the US Oncology and Global Respiratory businesses. Dr. Dube currently serves on the board of trustees for AIDS United and the board of directors for the Biotechnology Innovation Organization (BIO).
Dr. Dube has previously been named a Fortune magazine "40 Under 40: Ones to Watch" and one of the "Emerging Pharma Leaders" by Pharmaceutical Executive. He has also been named by the Financial Times as one of the "OUTstanding 100 LGBT+ Executives."
Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community.
Laura M. Clague, CPA
Chief Financial Officer
Ms. Clague has served as chief financial officer of Retrophin since November 2014. Ms. Clague has 30 years of experience as a financial executive, and oversees the company’s accounting, finance, IT and facilities functions. Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the vice president, corporate controller and principal accounting officer of Amylin for 10 years, when she also served as the chief financial officer of Amylin's collaboration with Eli Lilly and Company. Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation and KPMG. Ms. Clague currently serves on the board of directors of Genasys and Fluidigm. Ms. Clague is a Certified Public Accountant in the State of California, and received a B.S. in business administration from Menlo College.
Chief Commercial Officer
Peter Heerma has served as chief commercial officer at Retrophin since October 2019. He is responsible for leading the company’s commercial organization including commercialization strategy for approved products and pre-commercial planning for pipeline programs. He brings more than 20 years of global experience launching best-in-class therapies across therapeutic areas, managing pipeline and on-market product portfolios, and leading commercial and cross-functional teams at a number of top biopharmaceutical organizations.
Prior to joining Retrophin, Mr. Heerma served as global product general manager for oncology and cardiovascular products at Amgen where he led four cross-functional global product leadership teams with a revenue base exceeding $7 billion in 2018. He has also held various commercial leadership roles at AbbVie and Abbott Laboratories, most recently serving as AbbVie’s senior director of portfolio strategy for hepatology and nephrology. Prior to that, he served as senior director and asset team lead for HCV, diabetic nephropathy, and neuroscience development projects at AbbVie. While at Abbott Laboratories, Mr. Heerma held the titles of director of commercial strategy renal care, international marketing director for Zemplar, business unit manager of hospital products, and product manager for obesity and cardiovascular products.
He holds a Master of Science in European business administration and business law from the Lund University in Sweden and a Bachelor of Science in retail management and marketing from Stenden University in the Netherlands.
Noah L. Rosenberg, M.D.
Chief Medical Officer
Dr. Rosenberg has served as chief medical officer of Retrophin since July 2018 and is responsible for overseeing the company's clinical development, as well as clinical operations, pharmacokinetics, medical affairs, patient advocacy and pharmacovigilance. He brings more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization. Previously, Dr. Rosenberg served as chief medical officer at Medimetriks Pharmaceuticals where he was responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He also served as chief medical officer of Esperion Therapeutics, where he led the design, protocol implementation, execution and monitoring of innovative clinical programs. Prior to joining Esperion, Dr. Rosenberg served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, where he led the advancement of multiple late-stage clinical trials. Earlier in his career, he held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer. Dr. Rosenberg completed his internal medicine residency at The Icahn School of Medicine at Mount Sinai Hospital and holds an medical degree from the Drexel University College of Medicine and a B.A. from Johns Hopkins University.
William "Bill" Rote, Ph.D.
SVP, Research and Development
Dr. Rote has served as Senior Vice President of Research & Development (R&D) for Retrophin, Inc. since February 2017. He is responsible for discovery and translational research, regulatory affairs, quality assurance, biometrics, and technical operations including chemistry, manufacturing and controls (CMC). Prior to joining Retrophin, Dr. Rote led clinical development at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca. In this role, he was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management, and biostatistics. Prior to his role at Ardea, Dr. Rote held numerous positions of increasing responsibility at Amylin, including vice president and site head for R&D. He earned both his Ph.D. in pharmacology and B.S. in pre-medicine from Pennsylvania State University, and received postdoctoral training from the University of Michigan.
General Counsel and Corporate Secretary
Ms. Reed has served as senior vice president, general counsel and corporate secretary of Retrophin, Inc. since January 2017. She is responsible for overseeing the Company's general legal, intellectual property, government affairs and corporate compliance functions. Previously, Ms. Reed served as general counsel of Celladon Corporation, and prior to Celladon, served as General Counsel of Anadys Pharmaceuticals, Inc. until Anadys' acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California, and received her J.D. from Harvard Law School and her B.S. in business administration from the University of California, Berkeley.